Adjust insulin doses when patients step up to larger GLP-1 doses
In the STEP 1 trial, semaglutide led to an average 14.9% reduction in body weight over 68 weeks , far outperforming placebo (NEJM study on semaglutide for weight loss)
Weve spent the last two years drawing on Nooms deep expertise in behavior change to create the ultimate GLP-1 companion program to solve the medications twin challenges, persistence and muscle-mass loss, while also driving enhanced weight loss outcomes
AOD-9604, a specialized fragment of human growth hormone, supports fat breakdown and helps block new fat storage without impacting blood sugar or IGF-1
Most human studies focus on topical GHK-Cu application, while injection data comes primarily from animal models
Carver-Moore K, Broxmeyer HE, Luoh SM, Cooper S, Peng J, Burstein SA, Moore MW and de Sauvage FJ